Synthetic Human Parathyroid Hormone 1-34 pump

Synthetic Human Parathyroid Hormone 1-34 (PTH 1-34) pump is an investigational drug-delivery system that administers synthetic human PTH 1-34 (teriparatide) via continuous subcutaneous infusion using an insulin pump. Developed by the National Institutes of Health Clinical Center (NIH CC) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), this delivery method is designed to mimic the physiological, continuous secretion of endogenous parathyroid hormone. It acts as an agonist at the parathyroid hormone receptor 1 (PTH1R) to regulate calcium and phosphorus homeostasis. The therapy has been evaluated in Phase 2 clinical trials for the treatment of chronic hypoparathyroidism, including congenital and postsurgical forms, in both pediatric and adult patients. Compared to twice-daily subcutaneous injections, pump delivery provides more stable calcium homeostasis, reduces urinary calcium excretion, and lowers the required daily dose of PTH 1-34.

Other names

PTH 1-34 pumpPTH1-34 pumpPTH-1-34 pumpsynthetic human PTH 1-34 pumpsynthetic human parathyroid hormone 1-34 pumpteriparatide pump